President and chief scientific officer, Regeneron Pharmaceuticals
Appears in 2 stories
Leading Regeneron's olatorepatide registrational program
Hansoh Pharma presented full Phase III results for olatorepatide at the European Association for the Study of Diabetes meeting in Milan on October 2. Overweight and obese patients on the highest 15 mg dose lost 19.3% of their body weight on average by week 48, and the weight-loss curve had not flattened.
Updated Oct 2
Leading Regeneron's scientific strategy and Dupixent expansion
Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
